ProfileGDS5678 / 1418437_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 52% 53% 61% 56% 53% 52% 56% 59% 57% 47% 52% 56% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2761751
GSM967853U87-EV human glioblastoma xenograft - Control 23.2722152
GSM967854U87-EV human glioblastoma xenograft - Control 33.2976853
GSM967855U87-EV human glioblastoma xenograft - Control 43.5948761
GSM967856U87-EV human glioblastoma xenograft - Control 53.385556
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4136153
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3424552
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4163356
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5313959
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4331857
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1061447
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2350452
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.423156
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1103168